Lantheus Holdings, Inc. (LNTH), a leader in the radiopharmaceutical sector, witnessed a 9% decrease in its stock value on Tuesday following the announcement of its acquisition agreement with Evergreen Theragnostics, Inc.
Currently trading at $90.03, the stock has seen a decline of $8.28, representing an 8.42% drop on the Nasdaq.
The day's session opened with Lantheus shares priced at $99.91, compared to the previous close of $98.31. Throughout trading, the stock fluctuated between $89.85 and $100.99. Over the past year, share prices have ranged from a low of $51.79 to a high of $126.89.
The acquisition is structured as a cash-only transaction, involving an initial payment of $250 million, with the potential for additional milestone payments amounting to $752.5 million. While the strategic intent is to bolster Lantheus' product offerings, the financial magnitude of this venture appears to have given investors pause.
